ACO Expansion Might Change The Case For Investing In agilon health Stock (AGL)

• In late September 2026, agilon health reported that The Jackson Clinic and Springfield Clinic would expand their partnerships by joining agilon’s Senior Health Connect ACOs. This extends value-based care support to roughly 30,000 additional Traditional Medicare beneficiaries on top of existing Medicare Advantage panels.
• The moves deepen agilon health’s integration with large multi-specialty groups, tying more senior lives into full-risk accountable care models that rely heavily on the company’s technology, clinical pathways and operating infrastructure to manage complex conditions and control medical costs.
• We will now look at how agilon health’s expanded ACO partnerships with Jackson and Springfield Clinics might reshape the broader investment narrative.

Pursue where agilon health’s value-based care model might rhyme with other opportunities by scanning a curated group of 35 healthcare AI stocks.

agilon health Investment Narrative Recap

For agilon health, owning the stock means believing its value-based care model can scale while fixing past pain points in risk adjustment, medical cost trends and payer concentration. The short term hinge remains execution on medical margins and contract renegotiations in 2026. The new ACO partnerships help broaden Traditional Medicare reach, but do not remove those operational hurdles.

The biggest risk still sits in unstable medical economics and leadership turnover at a time when membership growth in Medicare Advantage has been selective and financial guidance withdrawn. These fresh ACO lives add volume and data. They only matter if agilon health converts that volume into predictable margins and more balanced payer exposure.

The Springfield Clinic expansion into agilon’s Senior Health Connect ACO is the clearest operational link to current catalysts. It ties roughly 21,000 more Traditional Medicare beneficiaries to agilon’s AI enabled platform, chronic care pathways and Medicare Shared Savings Program participation. That scale directly relates to the effort to improve risk adjustment accuracy and control inpatient and oncology drug spend.

You can view this announcement as a real time test of whether agilon health’s technology and clinical playbook can stabilize medical margins after prior compression. The ACO track record, including more than US$510 million in gross savings and a 96% average quality score in 2024, sets a reference point. The forward story now depends on repeating that level of performance while renegotiating payer terms and working through leadership turnover.

agilon health’s current analyst blueprint points to revenues of US$7.4b and earnings of US$77.9m by 2029, built on an assumed 7.6% yearly revenue growth rate and a swing in earnings of roughly US$329m from a loss of US$251.2m today to that projected profit level.

Uncover why agilon health’s fair value indicates a 41% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

One alternate view on agilon health puts contract risk front and center. The most pessimistic analysts were only modeling about US$6.9b of revenue and US$13.5m of earnings by 2029, with a very high implied P/E. Those assumptions predate this ACO news, so you should expect opinions to evolve and compare several angles yourself.

Explore 2 other agilon health fair value estimates, including one that suggests it could be worth just $118.33!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking for more investment ideas beyond agilon health?

Once you have a view on agilon health, it can help to line it up against other opportunities using the Simply Wall St Screener so you can compare risk, income potential and balance sheet strength side by side.

• If you want stocks that aim for growth with tighter budgets, scan a focused group of 8 elite penny stocks with strong financials that clears a financial quality bar instead of chasing hype alone.
• If value and resilience matter more to you than headlines, check out a curated set of 31 resilient stocks with low risk scores that pair lower risk scores with more robust fundamentals.
• If long term compounding through income appeals to you, review a hand picked selection of 7 dividend fortresses that target higher yields while still screening for stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]